Author Archives: rcschoen7

3rd Annual Tribute 21 – November 6th, 2015

Tribute 21 InviteResearch Down Syndrome is now LuMind Research Down Syndrome Foundation! Please visit our new site, http://www.lumindfoundation.org/tribute-21, to learn more and to purchase tickets for the 2015 Tribute 21 event!

Demarest Swim Club Fundraising in Support of LuMind Research Down Syndrome

banner_type_smaller copy

 

The Demarest Swim Club of Demarest, NJ, is participating in the 4th Annual Demarest Triathlon on June 7. This year the swim club is raising funds in support of Down syndrome cognitive research, with numerous sponsorships available. Half of the proceeds raised will go to LuMind Research Down Syndrome.

You can learn more about the triathlon and register for the event here

You can view sponsorship opportunities here

Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment

Cognition research funded by Research Down Syndrome and LuMind Foundation opens opportunities for individuals with Down syndrome and may identify potential treatments to lessen the impact of Alzheimer’s disease in persons with Down syndrome as well as the greater Alzheimer's community.

Marlborough, Massachusetts (PRWEB) March 12, 2015

Drumthwacket, New Jersey Governor’s residence, lit up in honor of Down syndrome cognition research on 3/21.

The Light the Way campaign will add support to RDS and LuMind efforts to educate and increase awareness and funding for Down syndrome cognition research. Research funded by the foundations is also making encouraging progress in identifying potential treatments to lessen the impact of Alzheimer’s disease in persons with Down syndrome. Alzheimer’s disease is 3-5 times more likely to occur, at an earlier age of onset, in individuals with Down syndrome.

In the last few years, researchers have made significant progress toward understanding and treating the cognitive issues associated with Down syndrome. This initiative has led to the discovery of multiple drug targets and supported the initiation of four clinical trials testing potential drug treatments. These studies now provide the promise of biomedical therapies for improving memory, learning and communication in individuals with Down syndrome, offering the potential for increased life opportunities.

In other WDSD recognitions, Research Down Syndrome and LuMind have joined in raising awareness of the promise of Down syndrome cognition research by organizing the World Down Syndrome Day 321 Virtual Run/Walk. On March 21, thousands will be joining in running or walking any distance recognizing 321, such as 3.21miles, 321 yards, 3.21 laps…and so on…all as a creative effort to promote the benefits of exercise on cognitive health and support Down syndrome cognition research. In addition, LuMind Foundation will be offering a 3:1 match for all donations received during the March 21, 2015 weekend.

About Research Down Syndrome and LuMind Foundation 
Research Down Syndrome and LuMind Foundation are non-profit foundations that support and fund Down syndrome cognition research conducted at leading institutions that are studying the basis of the intellectual impairments associated with Down syndrome, including Johns Hopkins University, Emory University, Stanford University, The University of Arizona, and the University of California, San Diego. Recent scientific advances have revolutionized this field of research, providing for the near term development of targeted medical therapies to treat the cognitive challenges associated with Down syndrome, improving memory, learning and communication, expanding and enhancing life opportunities, for people of all ages with Down syndrome. Research Down Syndrome and LuMind Foundation are legal corporate entities and 501(c) (3) nonprofit organizations designated by the Internal Revenue Code. For more information, please visit http://www.researchds.org orhttp://www.lumindfoundation.org.

LuMind Foundation and Research Down Syndrome Merge to Create Leading Source of Private Funding for Down Syndrome Cognition Research

LuMind Foundation and Research Down Syndrome have combined resources and programs. Together, these organizations contributed nearly $12 million to stimulate cognition research, resulting in the discovery of multiple drug targets and supporting the initiation of four clinical trials.

March 2, 2015 (Marlborough, Mass.) – The LuMind Foundation (formerly the Down Syndrome Research and Treatment Foundation – DSRTF) and Research Down Syndrome (RDS), worldwide leaders in advancing Down syndrome cognition research, together announce consolidation of the two organizations. The new foundation will pursue their shared mission more effectively and efficiently, and leverage the tremendous progress each has made to ignite Down syndrome cognition discoveries.

The merged organization will be named LuMind Research Down Syndrome Foundation. The LuMind Research Down Syndrome Foundation will be led by a national board of directors, consisting of board members from both organizations. Ryan Hartman will continue from his position as LuMind Foundation Chairman of the Board and Dan Flatley, Research Down Syndrome founder and Chairman, will serve as Vice Chairman.

Carolyn Cronin, recently named President and CEO, will lead the organization. Robert C. Schoen, Ph.D., formerly President, Research Down Syndrome, will be Director, Donor and Event Engagement. Dr. Michael Harpold will remain as the Chief Scientific Officer, leading the very successful research program. LuMind Research Down Syndrome Foundation will be consolidated and headquartered in Marlborough, Massachusetts.

“The LuMind Foundation and Research Down Syndrome have shared a mission of funding cognition research for people with Down syndrome and a Scientific Advisory Board for many years,” explained Hartman. “Our mission includes raising $25 million in five years to support Down syndrome research. Now we are coming together to speak with one voice on issues that are relevant to individuals and families in the Down syndrome community, and leverage resources to increase funds for research grants.” 

It is the mission of LuMind Research Down Syndrome Foundation to stimulate biomedical research to accelerate the development of treatments to significantly improve cognition, including memory, learning and speech, for individuals with Down syndrome enabling them to participate more successfully in school, lead more active and independent lives, and avoid the early onset of Alzheimer's Disease.

“Bringing the organizations together will increase our fundraising capacity and accelerate bio-medical programs that, in just a few years, have already demonstrated great success,” Flatley added.

Research funded by LuMind and Research Down Syndrome has led to the discovery of multiple pathways contributing to cognitive impairment that may serve as potential drug targets and four clinical trials testing possible drug therapies are currently underway.

About the LuMind Research Down Syndrome Foundation

LuMind Research Down Syndrome Foundation, formerly the Down Syndrome Research and Treatment Foundation (DSRTF) and Research Down Syndrome (RDS), is an international non-profit organization headquartered in Marlborough, Massachusetts, aimed at accelerating the development of treatments to significantly improve cognition, including memory, learning and speech, for individuals with Down syndrome. LuMind Research Down Syndrome Foundation is the leading source of private funding supporting research at major research centers, including Johns Hopkins Medicine, Stanford University, University of California, San Diego, and University of Arizona. Over the past decade, LuMind Research Down Syndrome Foundation has committed almost $12 million to fund results-driven research programs that will benefit children and adults with Down syndrome, and has been instrumental in the initiation of clinical trials now under way.

Tribute 21 – The 2nd Annual Masquerade Ball Benefiting RDS and the Tribute 21 Fund

Thanks again to Erin and Brendan Fry, and the entire Host Committee for Tribute 21, for the Second Annual Masquerade Ball Benefiting Research Down Syndrome and the Tribute 21 Fund, held on November 7 in Washington, DC.

Some pictures from Tribute 21 2014 are shared below, and here is a link to all the pictures, thanks to Bridget Conley, Jennifer Lust and Caitlin Taylor!

The evening's success is due in large part to our sponsors, who were so instrumental in making the evening such a resounding success….Thank You!

What an amazing night. Let's do it again.  We look forward to seeing you in 2015!

[dopwgg id=”6″]

Research Down Syndrome Announces 2014/2015 Grant Awards to Fund Down Syndrome Cognitive Research

Research Down Syndrome (RDS) has announced funding for five grants to support Down syndrome cognitive research.

RDS is committed to supporting the identification of the causes of the intellectual impairments associated with Down syndrome and to facilitating the development of pharmacological therapies to improve memory, learning and communication in persons with Down syndrome, and to address the increased likelihood of Alzheimer’s disease. Encouraging progress has been made over a very short time. Three human clinical trials are underway, less than a decade after the support of private foundations stimulated the progress of Down syndrome cognitive research.

Research Down Syndrome, among the leading sources of private funding for Down syndrome related cognitive research, prioritizes funding towards programs with a high probability of readily contributing to the development of safe and effective therapies.  Continued private donations are needed to support the constantly expanding research efforts that will lead to potential medical treatments.

The 2014/2015 RDS Research Grants include:

Johns Hopkins University School of Medicine: RDS Research Center Grant entitled “A Down Syndrome Center for Fundamental Research”

Emory University School of Medicine: RDS Research Center Grant entitled “The Down Syndrome Cognition Project”

University of California, San Diego School of Medicine: RDS Research Center Grant entitled “Defining the Genes and Mechanisms and Treatments for Neurodevelopmental and Neurodegenerative Causes of Cognitive Dysfunction in Down Syndrome”

University of Arizona: RDS Innovation Research Grant entitled “The Neuropsychology of Down Syndrome”

Stanford University School of Medicine: RDS Innovation Research Grant entitled “Mechanisms Underlying the Roles of Sleep and Circadian Rhythms in the Learning Disability of Down Syndrome”

VA Palo Alto Health Care System: RDS Innovation Research Pilot Grant entitled “Improving Adrenergic Signaling for the Treatment of Cognitive Dysfunction in Down Syndrome”

Detailed information on these grants can be found here.

Tribute 21 – The 2nd Annual Masquerade Ball Benefiting RDS and the Tribute 21 Fund